Gilead’s focus shifts from hepatitis C to CAR-T
Trading in shares of Daiichi Sankyo was suspended yesterday.
Allergan generics buyout left Teva with $35m debts
Tesaro and Puma are potential takeover targets
BMS will gain rights to preclinical cancer immunotherapy drugs.
Biotech’s Flublok is only FDA-approved cell-based flu jab
Could French biotech snap up remaining rights to pancreatic cancer drug?